Brevan Howard Capital Management LP
Position in RPRX — Royalty Pharma plc
CIK 1512857
ST. HELIER, Y9
Position in RPRX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,817,356
+$3,421,091 QoQ
Shares Held
79,578
+464.1% QoQ
Ownership
0.014%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Brevan Howard Capital Management LP holds $122,826,652 across 173 Biotechnology names. RPRX ranks #8 (3.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
81,570 | $6,057,388 | |
| 2 | ASND |
Ascendis Pharma A/S
|
26,200 | $5,992,726 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
204,845 | $4,785,179 | |
| 4 | MRNA |
Moderna, Inc.
|
89,594 | $4,551,375 | |
| 5 | RARE |
Ultragenyx Pharmaceutical Inc.
|
215,845 | $4,521,952 | |
| 6 | INCY |
Incyte Corp
|
46,448 | $4,371,685 | |
| 7 | DFTX |
Definium Therapeutics, Inc.
|
211,488 | $3,997,123 | |
| 8 | RPRX |
Royalty Pharma plc
This page
|
79,578 | $3,817,356 |
All Filings in RPRX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,817,356 | 79,578 | Shares | Defined | 2026-05-15 | |
| 2023-12-31 | $396,265 | 14,107 | Shares | Defined | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||